DRAFT MINUTES

Name of Meeting: DUR Board Meeting

Date of Meeting: November 6, 2003

Length of Meeting: 2:00 – 4:20 pm

Location of Meeting: DMAS Board Room

Members Present:

Elaine Ferrary, MS	Bill Rock, PharmD	Jennifer Edwards, PharmD
Geneva Briggs, PharmD	Sandra Dawson	Jane Settle, NP
Thomas Moffatt, MD	Catherine Keslo, MD	Jason Lynam, MD
Kelly Goode, PharmD		

(Not present: Mark Johnson, PharmD; Robert Friedel, MD; Matthew Goodman, MD)

DMAS Staff:

Patrick Finnerty	Cyndi Jones	Cheryl Roberts
Bryan Tomlinson	Javier Menendez, RPh	Rachel Cain, PharmD
Maryanne Paccione	Donna Garrett	

Contractor: Donna Johnson, Pharmacist First Health Services Corporation (FHSC)

Visitors:

Scott Blackman, Pfizer	Beth Carithers, Pfizer	Jim Oddona, Bristol Myers
Becky Snead, VPhA	David Butcher, Bristol Myers	

Call to Order:

Dr. Geneva Briggs, Chairperson, called the meeting to order at 2:00 PM and asked everyone to introduce themselves.

The Board reviewed and with a motion, approved minutes of the May 2003 meeting. (Minutes from the August meeting did not need to be approved do to the lack of a quorum at that meeting.)
Dr. Briggs stated the need for a vice chairperson to be elected before the close of the meeting.

Mr. Finnerty, DMAS Agency Director, thanked everyone for coming and for the hard work being done in implementing the pharmacy program changes. He identified the Pharmacy & Therapeutics Committee (P&T), and the Pharmacy Liaison Committee as working hard to support the development of these programs. He expressed DMAS' appreciation on the expertise and guidance given by the DUR Board.

Bryan Tomlinson, Director, DMAS Health Care Services Division, reiterated the importance of the Board. He spoke about the pharmacy section of DMAS being newly staffed. Mr. Tomlinson then introduced Javier Menendez, the new Pharmacy Manager for DMAS.

Mr. Menendez gave a presentation titled Virginia New Pharmacy Program. (A copy of the presentation follows the minutes.) His presentation covered Default Prescriber ID, PDL, Threshold/Polypharmacy and ProDUR Enhancements.

Mr. Menendez explained that the prescriber default number 9998888 will be terminated December 15, 2003 to enhance patient safety and quality care. There will be downloadable files on two websites and Medicall and First Health 800 numbers. However there will still be other default numbers for prescribers, which will not be terminated at this time. The other defaults are for non-participants, medical residents and out of state providers.

A threshold polypharmacy program (nine unique prescriptions) was approved by The Virginia General Assembly over a year ago. There may be certain disease states that will have an expedited Prior Approval. First Health generates daily reports to identify recipients exceeding the threshold, and also reviews profiles to identify questionable medications.

The Board was asked to give endorsement of the ProDUR enhancements. Discussion on early refills led to a split in opinion. Some thought the early refills should be left to the discretion of the pharmacist and not be a hard edit. Cheryl Roberts, Deputy Director of Operations, DMAS, stated changes could be made quarterly if necessary. Implementation will begin in January 2004. Cyndi Jones, Chief Deputy, DMAS, said health and safety is always the top concerns with any changes made with Medicaid. Discussion on Therapeutic Duplications was heavily centered on Narcotics and Benzodiazepines. Questions were raised on criteria for Narcotics and Benzodiazepines. Narcotics were excluded until further information could be reviewed. Ms. Johnson agreed to bring more information to the February Board meeting.
Dr. Moffat suggested and the Board agreed in principal to the use of the ProDUR enhancements but wanted a follow-up report in February.

Ms. Johnson presented criteria for the new drugs – Atazanavir, Rosuvastatin, Vardenafil and Gemifloxacin as well as the therapeutic class review of oral hypoglycemics. The Board approved the criteria with the following recommendations:

1. Atazanavir (Reyataz®)
    a. Over/Under Utilization add "X" for ProDUR (LR >4 days)
    b. Drug-Disease Interactions (ProDUR) – add AV Block

2. Rosuvastatin (Crestor®)
    a. Jane Settle will get and bring information from Patricia Fulco about using in combination with other anti retrovirals.

b. Drug-Drug Interactions – add dosage restrictions for cyclosporine and gemfibrozil

3. Vardenafil (Levitra®)
    a. Limited to 4 tablets/month
    b. Remove penile dysfunction from Drug-Disease Interactions
    c. Drug-Drug Interactions – add dosage restrictions to erythromycin, ketoconazole, indinavir, ritonavir.

4. Gemifloxacin (Factive®)
    a. Therapeutic Appropriateness – change "penicillin-resistant" to "multi-drug resistant"
    b. Incorrect Dosage – change >360 mg/d to >320 mg/d

5. Oral Hypoglycemics
    a. Over/Under Utilization all subclasses– make sure all early refill = < 75%
    b. Sulfonylureas 1st generation and 2nd generations
        i. Drug-Drug Interactions – Remove "anticoagulants" and "salicylates" from the retroDUR criteria.
        ii. Remove phenylbutazone from the ProDUR criteria
    c. Sub class Meglitinides remove "upper respiratory Infection" for adverse side effects.

The Board instructed Ms. Johnson to bring to the February meeting TD reports on the 10 classes of drugs of the top 1000 Therapeutic duplicates. These reports will be done in November and December. In January First Health will do a report on Antipsychotic drugs.

Ms. Briggs asked for nominations from the Board for a Vice Chairperson, Dr. Goode was nominated and elected unanimously.

The meetings for calendar year 2004 are as follows: February 5, May 6, August 5, and November 4.

The meeting was adjourned at 4:20 PM.